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Aims Although patients with syncope and bundle branch block (BBB) are at high risk of developing atrio-ventricular block,
syncope may be due to other aetiologies. We performed a prospective, observational study of the clinical outcomes
of patients with syncope and BBB following a systematic diagnostic approach.
Methods
and results
Patients with ≥1 syncope in the last 6 months, with QRS duration ≥120 ms, were prospectively studied following a
three-phase diagnostic strategy: Phase I, initial evaluation; Phase II, electrophysiological study (EPS); and Phase III,
insertion of an implantable loop recorder (ILR). Overall, 323 patients (left ventricular ejection fraction 56+12%)
were studied. The aetiological diagnosis was established in 267 (82.7%) patients (102 at initial evaluation, 113
upon EPS, and 52 upon ILR) with the following aetiologies: bradyarrhythmia (202), carotid sinus syndrome (20), ven-
tricular tachycardia (18), neurally mediated (9), orthostatic hypotension (4), drug-induced (3), secondary to cardio-
pulmonary disease (2), supraventricular tachycardia (1), bradycardia–tachycardia (1), and non-arrhythmic (7).
A pacemaker was implanted in 220 (68.1%), an implantable cardioverter deﬁbrillator in 19 (5.8%), and radiofrequency
catheter ablation was performed in 3 patients. Twenty patients (6%) had died at an average follow-up of 19.2+8.2
months.
Conclusion In patients with syncope, BBB, and mean left ventricular ejection fraction of 56+12%, a systematic diagnostic
approach achieves a high rate of aetiological diagnosis and allows to select speciﬁc treatment.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The most common aetiology of syncope in patients with bundle
branch block (BBB) is paroxysmal atrio-ventricular (A-V)
block.
1,2 However, other mechanisms such as ventricular tachycar-
dia (VT), supraventricular tachycardia (SVT), carotid sinus syn-
drome (CSS), neurally mediated, or orthostatic hypotension can
also cause syncope in this population.
2 In addition, some of
these patients are at high risk of sudden death, primarily related
to the presence and severity of structural heart disease.
3–6
The ﬁrst step in the diagnostic strategy is to identify patients
who are at high risk of sudden death.
7 In these patients, an
implantable cardioverter deﬁbrillator (ICD)
6,7 is indicated. The
diagnostic and therapeutic strategy in the remaining patients is
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European Heart Journal (2011) 32, 1535–1541
doi:10.1093/eurheartj/ehr071controversial. Some authors suggest that because the most
common cause of syncope in these patients is paroxysmal A-V
block, a pacemaker should be indicated,
8,9 whereas others
suggest following a comprehensive diagnostic approach that
aims to document the cause of syncope before indicating any
treatment.
2,7
The Bradyarrhythmia detection in BBB (B4) Study is a multicen-
tre, international, prospective, observational study that aims to
analyse the clinical outcomes of patients with syncope and BBB
following a systematic diagnostic approach, as recommended in
guidelines for the diagnosis and management of syncope of
European Society of Cardiology (ESC).
7
Methods
Patients
Patients were included if they had at least one syncope in the last 6
months and BBB on EGG with a QRS duration of ≥120 ms. Patients
with an indication for prophylactic ICD implantation due to low left
ventricular ejection fraction (LVEF) were excluded from the study.
Other exclusion criteria were pre-excitation, long QT syndrome,
Brugada’s syndrome, acute myocardial infarction, pregnancy, or life
expectancy ,1 year due to non-cardiac cause; patients who were
geographically or otherwise inaccessible for follow-up or who were
unwilling or unable to give informed consent were also excluded.
The study was approved by the institutional review boards and
signed informed consent was obtained from each patient at the time
of enrolment.
Study protocol
A systematic diagnostic strategy was designed with three consecutive
phases (Figure 1). Phase I consisted of initial evaluation including clinical
history, physical examination, 12-lead electrocardiogram (ECG),
measurement of blood pressure in supine and orthostatic positions,
and an echocardiogram. Electrocardiographic monitoring (in hospital
or Holter) was also recommended. Phase II consisted of an electro-
physiological study (EPS). Carotid sinus massage was performed on
all patients, but could be performed either at Phase I or at Phase II,
during EPS. Phase III consisted of implantable loop recorder (ILR)
implantation (Reveal Plus, Medtronic Inc.)
When the diagnosis was achieved at a given phase, speciﬁc measures
or treatment were instituted and patients were followed. When the
diagnosis was not achieved at a given phase, patients entered the
following phase.
Diagnostic criteria
According to the ESC guidelines,
7 the following aetiological diagnoses
were established: neurally mediated, when syncope was precipitated by
emotional triggers and was preceded by typical prodromal symptoms;
orthostatic hypotension, when syncope occurred in relation to orthos-
tatism and orthostatic hypotension was elicited
10; drug induced, when
there was a clear relationship between syncope and the introduction
of a new hypotensive drug or a change in dosage; secondary to cardi-
opulmonary disease, when syncope was clearly related to an acute
cardiopulmonary disorder; CSS, when syncope or near-syncope was
reproduced during or immediately after carotid sinus massage in the
presence of asystole .3 s and/or a fall in systolic blood pressure of
.50 mmHg; and arrhythmic syncope, when complete or advanced
A-V block, asystole .3 s, or the presence of sustained VT or rapid
SVT was documented,
11 with or without syncope.
12–14 Non-
arrhythmic syncope was diagnosed when sinus rhythm was documen-
ted during a syncopal episode.
The EPS was considered diagnostic with the following ﬁndings
7:
sinus node recovery time .1500 ms; corrected sinus node recovery
time .525 ms; baseline HV interval ≥70 ms; second- or third-degree
His–Purkinje block during incremental atrial pacing or after intrave-
nous class IC antiarrhythmic drugs or induction of sustained mono-
morphic VT or rapid SVT that provoked hypotension or reproduced
spontaneous symptoms.
Study endpoints
Clinical endpoints were recurrent syncope, documented spontaneous
arrhythmias, or death due to any cause.
All patients were followed quarterly during the ﬁrst 12 months.
Those with longer follow-up had additional visits at 18 and
24 months or at study closure. Whenever there was a syncopal recur-
rence, an unscheduled control visit was performed.
Statistical analysis
Data were sent by investigators via a dedicated Internet website that
maintained the database and issued data-clariﬁcation forms.
The occurrence of clinical endpoints was compared between
patients in whom diagnosis was achieved at Phase I or II, and who con-
sequently were treated according to the diagnosis, and patients in
whom an ILR was implanted after negative diagnostic work-up at
Phases I and II. Comparison between groups was performed with
Student’s t-test or the Mann–Whitney non-parametric ‘U’ test, as
appropriate, for continuous variables, and with Fisher’s exact test or
the x
2 test for proportions. Time to the onset of events was analysed
Figure 1 Proposed diagnostic strategy. Initial evaluation was
performed in all patients. Those in whom initial evaluation
achieved the diagnosed were treated accordingly. If initial evalu-
ation was not diagnostic, an electrophysiological study (EPS)
was performed: If it was diagnostic, patients were treated accord-
ing to the ﬁndings, and if it was negative, an implantable loop
recorder (ILR) was implanted.
A. Moya et al. 1536by means of the Kaplan–Meier survival curves, which were compared
using the log-rank test. Statistical signiﬁcance was set at the standard
value of P , 0.05. All reported P-values are two-tailed.
SPSS (SPSS Inc., Chicago, IL, USA) software version 12.0 statistical
package was used for the statistical analyses.
Results
Patients
Between January 2003 and January 2006, 423 patients were eligible
for the study (Figure 2). Overall, 100 patients were excluded from
the analysis due to the following reasons: 7 patients had incom-
plete data at baseline, 19 had incomplete follow-up (6 after initial
diagnosis, 6 after EPS, and 7 after ILR implantation), and 74 did
not follow the proposed algorithm: EPS was not performed in
20 and ILR was not implanted in 54. There were not statistical
differences in demographic data, the presence of structural heart
disease, the type of BBB or previous history of syncope,
between the 323 included and 100 excluded patients.
The study population consisted of 323 patients. The demo-
graphic and clinical characteristics are listed in Table 1. It can be
observed that patients who were diagnosed at Phase II had their
ﬁrst syncope episode at older age, had higher incidence of ischae-
mic or dilated cardiomyopathy, and had lower LVEF, but keeping in
normal values.
Patients were followed for 19.2+8.2 months (median 21.8;
inter-quartile range 12.1).
Aetiological diagnosis
At the end of follow-up, an aetiological diagnosis was established in
267 patients (82.7%; Table 2), with the following diagnoses: bra-
dyarrhythmia in 202 (paroxysmal A-V block documented at
initial evaluation or by ILR in 88, abnormal infrahisian ﬁndings at
EPS in 70, sick sinus syndrome or severe sinus bradycardia in 15,
alternating BBB documented at initial evaluation in 4, and not
speciﬁed in 25), CSS in 20, VT in 18, neurally mediated syncope
in 9, orthostatic hypotension in 4, drug-induced in 3, secondary
to cardiopulmonary disease in 2 (1 with severe aortic stenosis
and 1 with pulmonary thrombo-embolism), SVT in 1, bradycar-
dia–tachycardia syndrome in 1, and non-arrhythmic syncope in 7.
Treatments
At the end of follow-up, a pacemaker was implanted in 220 (68.1%)
patients, an ICD in 19 (5.8%), and radiofrequency catheter ablation
was performed in 3 patients (Table 3). In the remaining patients
who had other diagnoses, such as neurally mediated, orthostatic,
or drug-related syncope, aetiology-speciﬁc measures were applied.
Endpoints
Ofthe215patientsinwhomdiagnosiswasachievedatPhaseIorIIand
who were treated according to the ﬁndings, a syncopal recurrence
was observed in 15 (7%). In contrast, syncope recurred in 36 of 108
(33%) patients in whom an ILR was implanted (P , 0.001; Figure 3).
At follow-up, 5 of 14 (36%) patients in whom an ICD was
implanted due to inducible VT at EPS had appropriate discharges.
Figure 2 Flowchart of included patients. From 423 patients initially eligible, only 323 (represented in red) entered in the study. The reasons
for exclusion were incomplete data at baseline (7), lost of follow-up (LFU): 6 after initial diagnosis, 6 after electrophysiological study (EPS), and7
after implantable loop recorder (ILR) or lack of adherence to protocol (20 without diagnosis at initial evaluation in whom an EPS was not
performed and with negative EPS in whom ILR was not implanted).
Management of patients with syncope and BBB 1537The following arrhythmias were recorded with ILR (Table 2):
A-V block (36 patients: 20 during a syncopal episode and 16
asymptomatic); asystole (5 patients); VT or ventricular ﬁbrillation
(3 patients), and an episode of rapid atrial ﬁbrillation followed by
sudden asystole in 1 patient.
Twenty patients (6%) died at follow-up: 6 due to no cardiac
causes; 7 due to cardiac non-arrhythmic causes (5 due to heart
failure and 1 due to acute aortic dissection); 3, all with implanted
pacemakers, due to unknown causes; 1 had a sudden, undocumen-
ted syncope with a subdural hematoma, and 3 had sudden death
(all 3 with ILR; in 2, the device was not interrogated, and in 1, a
ventricular ﬁbrillation was documented). There was no difference
in mortality rate between patients diagnosed at Phase I or II,
who received appropriate treatment, compared with those who
had implanted ILR (6.0 vs. 6.5%, P ¼ 0.878).
No differences were found in mortality or syncope recurrence
with respect to the presence or absence of structural heart
disease, or the type of BBB.
Discussion
The main ﬁnding in this study is that in patients with syncope, BBB,
and preserved LVEF, the application of a systematic diagnostic
strategy in accordance with ESC guidelines achieves a high rate
of diagnosis (82.6%) with a low rate of mortality (6%), allowing
clinicians to institute aetiology-speciﬁc treatment.
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Table 1 Patient characteristics
Total Phase I Phase II Phase III P-value
Patients, n 323 102 113 108
Age in years, mean + SD 73 + 10 74 + 11 75 + 87 3 + 10 0.396
Male gender, n (%) 206 (63.8) 60 (58.8) 82 (72.6) 64 (59.3) 0.055
Total syncope episodes during lifetime, median (258–758 percentile) 2.0 (1.0–4.0) 2.0 (1.0–3.0) 2.0 (1.0–4.0) 3.0 (1.0–5.0) 0.076
Syncope episodes lasting 6 months, median (258–758 percentile) 2.0 (1.0–3.0) 1.0 (1.0–2.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 0.114
Age at ﬁrst syncope, mean + SD 72 + 11 72 + 13 74 + 97 0 + 12 0.034
History of pre-syncope, n (%) 125 (38.7) 46 (45.1) 34 (30.1) 45 (41.7) 0.058
Hospitalization for syncope, n (%) 230 (71.2) 74 (72.5) 86 (76.1) 70 (64.8) 0.168
Syncope without prodromes, n (%) 183 (56.7) 49 (48.0) 65 (57.5) 69 (63.9) 0.067
Syncope preceded by palpitations, n (%) 18 (5.6) 9 (8.8) 6 (5.3) 3 (2.8) 0.160
Trauma related to syncope (total), n (%) 96 (29.7) 24 (23.5) 34 (30.1) 38 (35.2) 0.181
Severe trauma related to syncope, n (%) 44 (13.6) 15 (14.7) 15 (13.3) 14 (13.0) 0.926
Baseline ECG, n (%)
LBBB 131 (40.6) 35 (34.3) 49 (43.4) 47 (43.5)
RBBB 67 (20.7) 26 (25.5) 24 (21.2) 17 (15.7)
RBBB with left anterior hemi-block 111 (34.4) 34 (33.3) 34 (30.1) 43 (39.8) 0.094
RBBB with left posterior hemi-block 8 (2.5) 2 (2.0) 5 (4.4) 1 (0.9)
Alternating LBBB and RBBB 5 (1.5) 4 (3.9) 1 (1.0) 0 (0.0)
RBBB with left anterior and posterior hemi-block 1 (0.3) 1 (1.0) 0 (0.0) 0 (0.0)
⎫
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎬
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎭
PR interval (ms), mean + SD 187 + 45 192.2 + 54 198.9 + 44.4 170 + 33.4 ,0.001
Structural heart disease, n (%) 161 (49.8) 48 (47.1) 71 (62.8) 42 (38.9) 0.005
Ischaemic heart disease 59 (18.3) 14 (13.7) 31 (27.4) 14 (13.0) 0.007
Valvular heart disease 38 (11.8) 13 (12.7) 17 (15.0) 8 (7.4) 0.198
Dilated cardiomyopathy 23 (7.1) 7 (6.9) 14 (12.5) 2 (1.9) 0.009
Hypertrophic cardiomyopathy 13 (4.0) 1 (1.0) 8 (7.1) 4 (3.7) 0.071
Hypertensive heart disease 49 (15.2) 19 (18.2) 18 (15.9) 12 (11.1) 0.304
Other 7 (2.2) 1 (1.0) 3 (2.7) 3 (2.8) 0.608
LVEF (%), mean + SD 56 + 12 56 + 12 52 + 14 60 + 10 ,0.001
LVEF , 40%, n (%) 26 (8.0) 8 (7.8) 16 (14.2) 2 (1.9) 0.004
Atrial ﬁbrillation, n (%) 34 (10.5) 16 (15.7) 12 (10.8) 6 (5.6) 0.057
Diabetes, n (%) 72 (22.3) 27 (26.5) 28 (24.8) 17 (15.7) 0.128
Hypertension, n (%) 221 (68.4) 71 (69.6) 76 (67.3) 74 (68.5) 0.933
Neurological disease, n (%) 42 (13.0) 15 (14.7) 11 (9.7) 16 (14.8) 0.440
Demographic and clinical characteristics of the study population. The second column (total) represents all population; in the following columns, there are the data of patients who
were diagnosed at Phase I, Phase II, or who entered at Phase III. LBBB, left bundle branch block; RBBB, right bundle branch block; LVEF, left ventricular ejection fraction.
A. Moya et al. 1538As expected, the most common cause of syncope in these
patients was bradyarrhythmia, mostly due to paroxysmal A-V
block. However, following this diagnostic strategy, other aetiolo-
gies of syncope were recognized in 17.6% of this population,
such as CSS, neurally mediated, or drug-related syncope, or
syncope secondary to VT, SVT, or cardiopulmonary disease.
In addition, an arrhythmic cause could be ruled out in several
patients who had a syncopal event documented by ILR.
The initial evaluation achieved a diagnosis in 25% of the studied
population. Although the most frequent diagnosis at EPS was a
bradyarrhythmia (76%), VT or SVT was induced in 14%. The role
of EPS in patients with BBB and preserved LVEF has been discussed.
The documentation of prolonged HV interval
15 or infrahisian block
with progressive atrial pacing
16 or after drug challenge with class IC
antiarrhythmic drugs
17 has been identiﬁed as a marker for pro-
gression to A-V block, with an acceptable speciﬁcity, but with low
sensitivity. In addition, the role of programmed ventricular stimu-
lation in these patients is controversial. Although Englund et al.
18
found that the induction of VT did not predict the occurrence of a
ventricular arrhythmia at follow-up, Olshansky et al.
19 found that
inducibility of VT increased the risk of sudden death at follow-up
and Link et al.
20 found that the absence of inducibility, especially in
patients with preserved LVEF, identiﬁed a group of patients with
low risk of sudden death at follow-up. In our study population, the
recurrence rate of syncope in patients treated according to the
diagnoses achieved at Phases I and II was low, suggesting that those
ﬁndings werespeciﬁc. In addition, the rate of appropriate discharges
in patients who received an ICD due to VT inducibility at EPS was
similar to the discharge rate described in different published series
in patients with ICD.
21,22 This similarity suggests that in our study,
inducibility identiﬁed the patients who were at risk of developing
VT at follow-up. However, the suggestion that the sensitivity of
EPS is relatively low was conﬁrmed, in our study, by the fact that in
45%ofthepatientswithanegativeEPS,anarrhythmiawasstilldocu-
mented by ILR. Again, ILR showed that bradyarrhythmia was the
most common cause of syncope in these patients, but it allowed us
to recognize some patients with VT, and also identiﬁed a non-
arrhythmic cause of syncope in some patients who otherwise may
never had been identiﬁed.
The potential risk of sudden death or severe cardiovascular
events may be a concern associated following this strategy. In
fact, several series suggested that the presence of abnormal ECG
or severe structural heart disease and speciﬁcally depressed
LVEF are risk factors for death or severe cardiovascular events in
short-term follow-up,
1,3–5,23 The relatively low mortality rate in
this older population can be attributed to the fact that patients
with depressed LVEF were probably not included and received
................................................................................
................................................................................
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Table 2 Diagnosis
Diagnosis n
Analysed patients, n ¼ 323
Initial evaluation
(Phase I), n ¼ 102
Bradyarrhythmia A-VB 52
Alt BBB 4
SSS 6
NS 13
CSS 6
Neurally mediated 9
Orthostatic
hypotension
4
Drug-induced 3
VT 3
Cardiopulmonary 2
EPS (Phase II), n ¼ 113 Bradyarrhythmia Infrahisian
abnormalities
70
SSS 4
NS 12
CSS 14
VT 12
SVT 1
ILR implantation
(Phase III), n ¼ 52
Bradyarrhythmia A-VB 36
SA 5
Non-arrhythmic 7
VT/VF 3
Brady/tachy 1
No diagnosis 56
EPS, electrophysiological study; ILR, implantable loop recorder; A-VB,
documentation of transient or advanced atrio-ventricular block, including type 2
second-degree atrio-ventricular block, with ECG, in hospital monitoring, Holter
recording (Phase I), or ILR (Phase III); Alt BBB, alternating bundle branch block;
SSS, sick sinus syndrome; NS, non-speciﬁed; CSS, carotid sinus syndrome; VT,
ventricular tachycardia; SVT, supraventricular tachycardia; VF, ventricular
ﬁbrillation; SA, sinus arrest. Infrahisian abnormalities includes HV interval ≥70 ms
or the presence of infrahisian block with atrial pacing or drug challenge.
................................................................................
................................................................................
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Table 3 Treatments according to different phases
Treatment n
Analysed patients, n ¼ 323
Initial evaluation (Phase I) PMK 82
General measures/drug
modiﬁcation/PCM/other
16
ICD 2
RFA 1
AVR 1
EPS (Phase II) PMK 97
ICD 14
RFA 1
No active treatment 1
ILR implantation (Phase III) PMK 41
ICD 3
RFA 1
No active treatment 51
EPS, electrophysiological study; ILR, implantable loop recorder; PMK, pacemaker
implantation; ICD, implantable cardioverter deﬁbrillator; RFA, radiofrequency
catheter ablation; AVR , aortic valve replacement; PCM, physical counterpressure
manoeuvres.
Management of patients with syncope and BBB 1539an ICD. This explains why the mean LVEF is 56+12, with very few
patients with LVEF lower than 40%. In addition, most deaths were
due to non-cardiac or non-arrhythmic causes. Some patients who
received an implanted pacemaker died of unexplained causes,
suggesting that bradyarrhythmia was not the cause of death in
these patients. Admittedly, three patients died with an ILR
implanted: in at least one of them, a ventricular ﬁbrillation was
documented that would not have been prevented by a pacemaker;
in the other two, the cause of death remains unknown.
It can be argued that with a longer follow-up, some more
patients would have syncopal recurrence or asymptomatic arrhyth-
mias recorded by ILR, allowing clinicians to increase the number of
patients with a ﬁnal diagnosis.
24–27 This is true, but in any case
reinforces the value of this diagnostic strategy, encouraging clini-
cians to monitor these patients and not to initiate any treatment
until a deﬁnite diagnosis is achieved.
The study was not designed to determine whether this diag-
nostic strategy was better than implanting a pacemaker in the
majority of patients, and consequently, we cannot declare
which option might be better. Owing to the low mortality
and low syncopal recurrence rate observed when following
this strategy in this speciﬁc population, only a controlled trial
including a great number of patients would be able to answer
this question.
Admittedly, some patients were excluded from the study
because in those patients the suggested algorithm was not fol-
lowed. As this was an observational study, investigators could
not be forced to follow the protocol in all patients, and a selection
bias cannot be excluded. However, demographic and clinical
characteristics of excluded patients were similar to those included
patients, decreasing the probability of a selection bias.
In conclusion, in patients with syncope, BBB, and relatively
preserved LVEF, a diagnostic strategy consisting of initial clinical
evaluation, followed by EPS and, if negative, implantation of an
ILR, achieves a high rate of aetiological diagnosis. The high diag-
nosis rate in turn allows clinicians to select a speciﬁc treatment
and to avoid unnecessary pacemaker implantation without a high
rate of cardiovascular events or mortality. Whether this strategy
is better than the strategy of implanting pacemakers into all
patients with this clinical proﬁle cannot be determined with
current data.
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Appendix
The following persons participated in the B4 study.
Coordinating Committee: R.G.-C. (Chair), A.M., F.A.,
M. Brignole, J.B., C.M., and X.N. Database electronic management:
Remote Data Entry System, SL, Barcelona, Spain. Clinical monitors:
M.P. Lo ´pez, G. Monzo ´n, and N. Grovale; Statistical analysis:
M. Martı ´n, T. de Santo.
Centres and investigators (in the order of number of recruited
patients): Ospedale S. Giuseppe, Empoli, Italy: A.D.R.; Hospital
Clinic, Barcelona: J.B., L.M., I. Molina; Hospital General, Castello ´n,
Spain: A.B.-N.; Hospital General, Albacete, Spain: J.G.-S.; Hospital
Clı ´nico, Valencia, Spain: R.G.-C., R.R.-G.; Ospedale Maggiore della
Carita `, Novara, Italy: M.B., E. Occhetta; Complejo Hospitalario
de Ciudad Real, Ciudad Real, Spain: J. Benezet; Hospital Virgen
de la Arrixaca, Murcia, Spain: J. Lacunza, A. Garcı ´a-Alberola;
Arrhythmologic Centre, Ospedali del Tigullio, Lavagna, Italy: M.
Brignole, F.C.; Hospital Vall d’Hebron, Barcelona, Spain: A.M.,
Figure 3 The Kaplan–Meier survival curve of syncopal recurrences in patients in which the diagnosis was achieved at Phase I or II and were
treated according to the diagnosis (black line) and those in which an ILR was implanted after a negative work-up in Phase I or II. Patients diag-
nosed and treated had a signiﬁcant reduction or syncopal recurrence when compared with those with an ILR implanted.
A. Moya et al. 1540N. Rivas; Arcispedale Santa Maria La Nuova, Reggio Emilia, Italy:
C.M.; Ospedale Grassi, Ostia, Italy: F.A.; Ospedale Grassi, Ostia,
Italy: M. Santini; Hospital Municipal, Badalona, Spain: F. Planas; Hos-
pital Virgen de las Nieves, Granada, Spain: M. Alvarez, L. Tercedor;
Hospital Miguel Servet, Zaragoza, Spain: A. Asso; Hospital Xeral
Cı ´es, Vigo, Spain: X. Beiras, E. Garcı ´a; Ospedale Umberto I,
Mestre, Italy: F. Giada, A. Raviele; Hospital Lluis Alcan ˜iz, Xativa,
Spain: M. Rodriguez; Hospital Juan Ramo ´n Jime ´nez, Huelva, Spain:
R. Barba; Ospedale Santo Spirito in Sassia, Roma, Italy:
L. Pandolfo, A. Porzio; Ospedale S. Camillo De Lellis, Rieti, Italy:
S. Orazi; Hospital Puerta de Hierro, Madrid, Spain:
I. Fernandez-Lozano, J. Toquero; Hospital Virgen del Rocı ´o,
Sevilla, Spain: G. Baro ´n, F. Erra ´zquin, A. Pedrote; Hospital Santa
Marı ´a, Lleida, Spain: J. Toma ´s; Clinica Cardiologica Universita de
Padova, Padova, Italy: G. Buja, A. Folino; Ospedale San Gerardo
del Tintori, Monza, Italy: S. De Ceglia, A. Vicenti; Hospital
Clı ´nico San Carlos, Madrid, Spain: J. Villacastı ´n; Ospedale Careggi,
Firenze, Italy: A. Ungar; Hospital General, Valencia, Spain: J. Roda,
V. Palanca; Hospital La Paz, Madrid, Spain. J.L. Merino,
R. Peinado; Hospital Ramo ´n y Cajal, Madrid, Spain: A.H. Madrid;
C. Moro; Hospital del Mar, Barcelona, Spain: J. Martı ´.
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